GSK PLC (GSK)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

1,356.00p

Buy

1,356.50p

arrow-down-41.50p (-2.97%)

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Prices updated at 13 May 2025, 16:43 BST
| Prices minimum 15 mins delay
|
Prices in GBX
FTSE All-Share
arrow-up0.06%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Sir Jonathan Richard Symonds CBE
CEO
Dame Emma N. Walmsley
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
68,629
Head office
79 New Oxford Street
London
United Kingdom
WC1A 1DG
mobile
+44 2080475000
letter
company.secretary@gsk.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Charles A. Bancroft
Non-Executive Director, Senior Independent Director
---0.33m-
Sir Jonathan Richard Symonds CBE
Non-Executive Director, Chairman
---0.78m-
Dr. Hal V Barron
Non-Executive Director
---0.46m-
Ms. Wendy Becker
Non-Executive Director
-----
Dr. Vishal Sikka
Non-Executive Director
-----
Ms. Elizabeth McKee Anderson
Non-Executive Director
-----
Dr. Anne Beal
Non-Executive Director
-----
Dr. Harry C Dietz
Non-Executive Director
-----
Dr. Jeannie Lee
Non-Executive Director
-----
Dr. Gavin Screaton
Non-Executive Director
-----
Ms. Julie Brown
Executive Director, Chief Financial Officer
-----
Dame Emma N. Walmsley
Executive Director, Chief Executive Officer
-----
Mrs. Victoria Anne Whyte
Company Secretary
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Vanguard Group Inc118,266,3215.224641942885-30 Apr 20252.91
Dodge & Cox105,684,2409.0094413180000-30 Apr 20252.60
BlackRock Fund Advisors81,675,23521.48667-7184393-30 Apr 20252.01
Dodge & Cox International Stock Fund77,964,6202.90861112930016.65182430 Apr 20251.92
Vanguard Total Intl Stock Idx Fund56,653,0390.233124084550.72621230 Apr 20251.39

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
06 May 2025SaleDame Emma N. Walmsley1448.9679,3022,419,5640.06-
06 May 2025Transfer inDame Emma N. Walmsley--2,425,0370.06As advised by the company
16 Apr 2025DDame Emma N. Walmsley1275.0024,5312,413,3940.06Dividend Reinvestment Plan(DRIP)
16 Apr 2025DDame Emma N. Walmsley1275.0016,6262,409,7680.06Dividend Reinvestment Plan(DRIP)
16 Apr 2025DDame Emma N. Walmsley1275.0021,7012,411,4700.06Dividend Reinvestment Plan(DRIP)
16 Apr 2025DMs. Julie Brown1275.009,359170,9640.00Dividend Reinvestment Plan(DRIP)
16 Apr 2025DMs. Julie Brown1275.0010,889170,2300.00Dividend Reinvestment Plan(DRIP)
15 Apr 2025PurchaseDr. Hal V Barron18.0064,881741,7700.02ADRs
11 Apr 2025PurchaseDr. Hal V Barron17.06990738,1650.02ADRs
11 Apr 2025PurchaseMr. Charles A. Bancroft17.065,93784,4570.00ADRs
11 Apr 2025PurchaseDr. Vishal Sikka17.063,34418,5840.00ADRs
11 Apr 2025PurchaseDr. Jesse Goodman, M.D.,M.P.H.17.0675138,8120.00ADRs
11 Apr 2025PurchaseMs. Elizabeth McKee Anderson17.068874,9080.00ADRs
11 Apr 2025PurchaseDr. Anne Beal17.067519,3100.00ADRs
11 Apr 2025PurchaseDr. Harry C Dietz17.067518,7380.00ADRs
11 Apr 2025PurchaseDr. Jeannie Lee17.063412,1100.00ADRs
10 Apr 2025PurchaseDame Emma N. Walmsley1261.531262,403,8590.06Partnership
10 Apr 2025DDame Emma N. Walmsley1306.6859,5852,408,4640.06Dividend Reinvestment Plan(DRIP)
10 Apr 2025DDame Emma N. Walmsley1312.694592,403,9040.06Dividend Reinvestment Plan(DRIP)
10 Apr 2025Transfer inDame Emma N. Walmsley--2,403,8690.06Matching
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.